Sab Biotherapeutics Stock Buy Hold or Sell Recommendation
| SABSW Stock | USD 0.03 0 14.34% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding SAB Biotherapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell SAB Biotherapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for SAB Biotherapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out SAB Biotherapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide. Note, we conduct extensive research on individual companies such as SAB and provide practical buy, sell, or hold advice based on investors' constraints. SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
SAB |
Execute SAB Biotherapeutics Buy or Sell Advice
The SAB recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on SAB Biotherapeutics. Macroaxis does not own or have any residual interests in SAB Biotherapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute SAB Biotherapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
SAB Biotherapeutics Trading Alerts and Improvement Suggestions
| SAB Biotherapeutics is way too risky over 90 days horizon | |
| SAB Biotherapeutics has some characteristics of a very speculative penny stock | |
| SAB Biotherapeutics appears to be risky and price may revert if volatility continues | |
| SAB Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (25.38 M). | |
| SAB Biotherapeutics generates negative cash flow from operations |
SAB Biotherapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. SAB analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. SAB analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
SAB Biotherapeutics Returns Distribution Density
The distribution of SAB Biotherapeutics' historical returns is an attempt to chart the uncertainty of SAB Biotherapeutics' future price movements. The chart of the probability distribution of SAB Biotherapeutics daily returns describes the distribution of returns around its average expected value. We use SAB Biotherapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of SAB Biotherapeutics returns is essential to provide solid investment advice for SAB Biotherapeutics.
| Mean Return | 3.04 |
| Value At Risk | -38.46 |
| Potential Upside | 50.19 |
| Standard Deviation | 31.34 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of SAB Biotherapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
SAB Biotherapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to SAB Biotherapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that SAB Biotherapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a SAB stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 3.04 | |
β | Beta against Dow Jones | 0.21 | |
σ | Overall volatility | 24.59 | |
Ir | Information ratio | 0.1 |
SAB Biotherapeutics Volatility Alert
SAB Biotherapeutics is showing large volatility of returns over the selected time horizon. SAB Biotherapeutics is a penny stock. Although SAB Biotherapeutics may be in fact a good investment, many penny stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in SAB Biotherapeutics. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on SAB instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.SAB Biotherapeutics Fundamentals Vs Peers
Comparing SAB Biotherapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze SAB Biotherapeutics' direct or indirect competition across all of the common fundamentals between SAB Biotherapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as SAB Biotherapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of SAB Biotherapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare SAB Biotherapeutics to competition |
| Fundamentals | SAB Biotherapeutics | Peer Average |
| Return On Equity | -1.75 | -0.31 |
| Return On Asset | -0.79 | -0.14 |
| Operating Margin | (34.23) % | (5.51) % |
| Number Of Shares Shorted | 1.18 K | 4.71 M |
| Price To Earning | 0.21 X | 28.72 X |
| Revenue | 2.24 M | 9.43 B |
| Gross Profit | (25.38 M) | 27.38 B |
| EBITDA | (38.13 M) | 3.9 B |
| Net Income | (42.19 M) | 570.98 M |
| Total Debt | 5.91 M | 5.32 B |
| Book Value Per Share | 4.00 X | 1.93 K |
| Cash Flow From Operations | (25.12 M) | 971.22 M |
| Earnings Per Share | 0.29 X | 3.12 X |
| Number Of Employees | 57 | 18.84 K |
| Beta | 0.45 | -0.15 |
| Total Asset | 83.94 M | 29.47 B |
| Retained Earnings | (90.06 M) | 9.33 B |
| Working Capital | 48.09 M | 1.48 B |
| Net Asset | 83.94 M |
Note: Acquisition by Eddie Sullivan of 1740 shares of SAB Biotherapeutics at 0.88 subject to Rule 16b-3 [view details]
SAB Biotherapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as SAB . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About SAB Biotherapeutics Buy or Sell Advice
When is the right time to buy or sell SAB Biotherapeutics? Buying financial instruments such as SAB Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having SAB Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Automobiles and Trucks Thematic Idea Now
Automobiles and Trucks
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Automobiles and Trucks theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Automobiles and Trucks Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.